Users Online:
2178
Home
|
About the Journal
|
Instructions
|
Current Issue
|
Back Issues
|
Reader Login
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
Citation statistics : Table of Contents
2020| April | Volume 23 | Issue 7
Online since
April 24, 2020
Archives
Previous Issue
Next Issue
Most popular articles
Most cited articles
Show all abstracts
Show selected abstracts
Export selected to
Cited
Viewed
PDF
VIEW POINT
Consensus statement – suggested recommendations for acute stroke management during the COVID-19 pandemic: Expert group on behalf of the indian stroke association
Rohit Bhatia, PN Sylaja, MV Padma Srivastava, Dheeraj Khurana, Jeyaraj Durian Pandian, Vinit Suri, VG Pradeep Kumar, S Kumaravelu, Vikram Huded, Nirmal Surya, Arvind Sharma, Subhash Kaul
April 2020, 23(7):15-23
DOI
:10.4103/aian.AIAN_302_20
The ongoing pandemic of COVID-19 is a global public health emergency. This has led to challenges for healthcare facilities to optimally manage other important medical emergencies. Stroke is an important public health emergency with significant mortality and morbidity. Timely treatment of acute stroke is critical to prevent disability. The current expert consensus statement on behalf of the Indian Stroke Association outlines the issues and suggestions related to the management of stroke during this ongoing COVID-19 pandemic.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
7
9,079
925
AIAN REVIEW
COVID 19: Neuromuscular manifestations
Rajesh Benny, Satish V Khadilkar
April 2020, 23(7):40-42
DOI
:10.4103/aian.AIAN_309_20
COVID-19 pandemic is ongoing and information on the neurological aspects of this viral infection is being gathered. Neuromuscular manifestations have been reported uncommonly in these early stages of the analysis. This manuscript studies the available information on the neuromuscular manifestations of COVID-19.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
6
6,628
162
LETTERS TO THE EDITOR
COVID-19 and epilepsy
Sora Yasri, Viroj Wiwanikit
April 2020, 23(7):43-43
DOI
:10.4103/aian.AIAN_254_20
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
6
3,675
120
VIEW POINT
The challenge of managing parkinson's disease patients during the COVID-19 pandemic
Divyani Garg, Rajinder K Dhamija
April 2020, 23(7):24-27
DOI
:10.4103/aian.AIAN_295_20
The 2019 novel coronavirus (nCoV) pandemic is rapidly developing across the globe and new information is emerging expeditiously and constantly, particularly in relation to neurological illnesses. Both central and peripheral nervous system involvement has been reported including headache, dizziness, hyposmia/anosmia, taste disturbances, seizures, stroke, alteration of the sensorium, and even acute hemorrhagic necrotizing leukoencephalopathy. Varying degrees of olfactory disturbances may pre-empt the diagnosis of COVID-19. Although no direct effect of 2019 nCoV has been reported yet on Parkinson's disease, there are enormous possible indirect effects and implications. We examine the potential effects and challenges posed by this pandemic to individuals with Parkinson's disease, particularly in the Indian context where telecommunication access or support group access may be lacking for these patients. Additionally, lockdown and social distancing may pose hurdles in the provision of optimum medical therapy, particularly if patients experience motor and non-motor deteriorations due to diverse reasons.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
5
8,286
210
AIAN REVIEW
Managing migraine in the times of COVID-19 pandemic
Debashish Chowdhury, Debabrata Datta
April 2020, 23(7):33-39
DOI
:10.4103/aian.AIAN_296_20
COVID-19 pandemic is an emerging, rapidly evolving situation. Migraine is one of the commonest and highly disabling chronic neurological diseases in the world. During the pandemic and lockdown, migraine patients are facing an enormous problem in getting optimum care because of difficulty in access, forced social isolation, and encountering a health system that is getting rapidly overwhelmed. It is important that they must be protected by minimizing their visits to the clinics and emergency departments. Paradoxically multiple triggers are in operation which is likely to increase their headache frequency. Hence physicians should be made aware of the new rules of the game in treating migraines during this time of the pandemic so that these patients get optimum treatment and care and don't feel left out. This review tries to answer a series of questions related to managing migraines in the times of COVID-19 pandemic.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
4
10,897
234
2019-NCoV: What every neurologist should know?
Nitika Mahajan, Monika Singla, Balveen Singh, Venkatesh Sajja, Parth Bansal, Birinder Paul, Parveen Goel, Rahul Midha, Rajinder Bansal, Gagandeep Singh
April 2020, 23(7):28-32
DOI
:10.4103/aian.AIAN_210_20
The 2019 novel Corona Virus pandemic beginning from Wuhan, China primarily affects the respiratory tract but its has impacted clinical practice across a range of specialities including neurology. We review the bearing of the 2019 NCoV infection on neurological practice. Neurological manifestations are less common than respiratory manifestations, yet conspicuous, affecting nearly over a third of hospitalized individuals. These may be classified in to early – headache, dizziness, hyposmia and hypogeusia and late – encephalopathy. Rarely but surely, a very small proportion of infected individuals might present with stroke. Certain neurological conditions, including cerebrovascular disease in both China and Italy and dementia in Italy predispose to infection and more severe manifestations, requiring intensive care unit admission. There is no convincing evidence that the manifestations, course and outcome of various neurological disorders is impacted by 2019 nCoV infection. Concerns of an increased risk of febrile seizures offset by a reduced frequency of infection in the paediatric age group. Individuals with multiple sclerosis might potentially experience both true and pseudorelapses. Besides a direct effect, 2019 nCoV has tremendously affected neurological care by disrupting the continuity of care and the availability of neurological medicines worldwide. Neurologists should respond to this challenge by developing and sustaining innovative methods of providing care as well as alerting the society at large to adopt measures to contain the spread of 2019 nCoV.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
4,468
269
EDITORIAL COMMENTARY
The socially distanced social animal – in the new Covid-19 Era
Lakshmi Narasimhan Ranganathan, MM Arun Shivaraman, Guhan Ramamurthy, R Shrivarthan
April 2020, 23(7):1-4
DOI
:10.4103/aian.AIAN_263_20
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
-
5,193
292
LETTERS TO THE EDITOR
COVID-19 and underlying cerebrovascular disease: Analysis on association
Pathum Sookaromdee, Viroj Wiwanitkit
April 2020, 23(7):43-44
DOI
:10.4103/aian.AIAN_280_20
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
-
2,192
98
Alteration of consciousness as initial presentation in COVID-19: Observation
Beuy Joob, Viroj Wiwanitkit
April 2020, 23(7):44-44
DOI
:10.4103/aian.AIAN_123_20
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
-
2,433
152
VIEW POINT
Consensus statement on immune modulation in multiple sclerosis and related disorders during the covid-19 pandemic: Expert group on behalf of the indian academy of neurology
Bhatia Rohit, MV Padma Srivastava, Dheeraj Khurana, Lekha Pandit, Thomas Mathew, Salil Gupta, M Netravathi, Sruthi S Nair, Gagandeep Singh, Bhim S Singhal
April 2020, 23(7):5-14
DOI
:10.4103/aian.AIAN_259_20
Knowledge related to SARS-CoV-2 or 2019 novel coronavirus (2019-nCoV) is still emerging and rapidly evolving. We know little about the effects of this novel coronavirus on various body systems and its behaviour among patients with underlying neurological conditions, especially those on immunomodulatory medications. The aim of the present consensus expert opinion document is to appraise the potential concerns when managing our patients with underlying CNS autoimmune demyelinating disorders during the current COVID-19 pandemic.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
-
6,636
327
About this journal
Editorial Board
Online Submission
Current Issue
Archives
Ahead of print
Instructions to Authors
Subscription
Alerting
Feedback
About us
|
Contact us
|
Ahead Of Print
|
Online Submission
|
Sitemap
|
Advertise
|
What's New
|
Feedback
|
Disclaimer
|
Privacy Notice
© 2006 - Annals of Indian Academy of Neurology | Published by Wolters Kluwer -
Medknow
Online since 1
st
March, 2006